A puff, but not just any
At Vaping Post, we haven’t reviewed many disposable vapes. While disposables have benefits for users seeking the simplest, ready-to-use product, the ecological impact is significant since each battery is used only until the e-liquid reservoir is empty. Beyond being disposable, the Galaxy 15000 introduces a new molecule that might soon appear in traditional e-liquids, which is why we’re taking a closer look.
Technical Specifications
| Characteristic | Details |
|---|---|
| Pod Dimensions | 83 x 27.4 x 52.6 mm |
| Pod Weight | 78 g |
| Charging | USB-C |
| Battery | 650 mAh |
| Puffs | 15 000 |
| Tank Capacity | 15 ml |
Box includes:
- The puff
A puff with a nicotine-like effect
The Galaxy 15000 has the classic look of a disposable vape. Right away, you’ll notice the NoNic® 20 mg effect marking. With this, Aromaking offers an alternative to traditional nicotine.
Each device contains a substance named 6-methylnicotine, intended to deliver sensations similar to nicotine. Technically, it’s not nicotine, but it has comparable effects, particularly in terms of throat hit. Our test model simulates a 20 mg/ml effect, and each puff delivers a surprisingly strong sensation. It’s intense, with a powerful throat tingling. Note that the Galaxy 15000 is restricted to adults only.
Underneath the Galaxy 15000, there is a button to turn the device on and off. It also has a boost mode for an even stronger throat hit. Using this mode halves the advertised puff count to 7,500 instead of 15,000. A USB-C connector enables fast charging of the 650 mAh internal battery. The tank holds 15 ml, and a mesh coil is used for vapor production.
An animated display shows battery and liquid levels. Vapor is produced through simple inhalation, with a fairly tight, indirect airflow.
What is 6-Methylnicotine?
6-Methylnicotine is a nicotine analogue, meaning nicotine with a slightly modified molecular structure. In the United States, this new molecule is already present in some products. Manufacturers are interested because American regulations prohibit certain molecules listed specifically by name. By creating a new molecule, it takes time for it to be added to regulatory lists, allowing for its sale in the meantime.
However, one should note the implications of consuming these new molecules. Altering their structure, even slightly, creates a molecule previously unknown to science. Currently, studies on the effects of 6-methylnicotine are extremely limited, with research only beginning. Below is a list of published works we have found.
- Qi, H., Chang, X., Wang, K., Xu, Q., Liu, M., & Han, B. (2023). Comparative analyses of transcriptome sequencing and carcinogenic exposure toxicity of nicotine and 6-methyl nicotine in human bronchial epithelial cells. Toxicology in Vitro. https://doi.org/10.1016/j.tiv.2023.105413
- Tronci, V., Vronskaya, S., Montgomery, N., Mura, D., Balfour, D. J. K., & Vollenweider, F. X. (2010). The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine. Psychopharmacology, 210(3), 307–318. https://doi.org/10.1007/s00213-010-1868-x
- Jordt, S. E., Jabba, S. V., Silinski, P., & Berman, M. L. (2024). An electronic cigarette pod system delivering 6-methyl nicotine, a synthetic nicotine analog, marketed in the United States as “PMTA exempt”. Tobacco Control. https://doi.org/10.1136/tc-2023-058469
- Erythropel, H. C., Jabba, S. V., Silinski, P., & Anastas, P. T. (2024). High variability in nicotine analog contents, misleading labeling, and artificial sweetener in new e-cigarette products marketed as “FDA-exempt”. MedRxiv. https://doi.org/10.1101/2023.11.21.23298778
- Wang, D. X., & Booth, H. (1998). Structure–activity relationships for nicotine analogs comparing competition for nicotine binding and psychotropic potency. Drug Development Research, 45(1), 10-22. https://doi.org/10.1002/(SICI)1098-2299(199809)45:1<10::AID-DDR2>3.0.CO;2-G
In Summary
What we like
- Strong throat hit
- Easy to use
- Nicotine alternative
What we dislike
- Fully disposable
